A5050524578- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Cancer, Lipids, and Metabolism
- BRCA gene mutations in cancer
- Immune Cell Function and Interaction
- RNA modifications and cancer
- Peroxisome Proliferator-Activated Receptors
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
- Immune cells in cancer
- Cancer Research and Treatments
- Metabolism, Diabetes, and Cancer
- Genomic variations and chromosomal abnormalities
- Hippo pathway signaling and YAP/TAZ
- Pancreatic function and diabetes
- RNA Research and Splicing
- Liver Disease Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Endoplasmic Reticulum Stress and Disease
- Angiogenesis and VEGF in Cancer
- Mitochondrial Function and Pathology
KU Leuven
2015-2024
MRC Weatherall Institute of Molecular Medicine
2014-2020
University of Oxford
2014-2020
Cancer Research UK
2020
John Radcliffe Hospital
2012-2019
VIB-KU Leuven Center for Cancer Biology
2015-2018
Vlaams Instituut voor Biotechnologie
2016
Oxford Research Group
2016
Amsterdam UMC Location Vrije Universiteit Amsterdam
2010-2011
Cancer Center Amsterdam
2011
Fatty acid-binding protein 4 (FABP4) is an adipogenic and implicated in atherosclerosis, insulin resistance, cancer. In endothelial cells, FABP4 induced by VEGFA, inhibition of blocks most the VEGFA effects. We investigated DLL4-NOTCH-dependent regulation human umbilical vein cells gene/protein expression interaction analyses following inhibitor treatment RNA interference. found that directly NOTCH. Stimulation NOTCH signaling with recombinant DLL4 led to induction, independently VEGFA....
Fatty acid binding protein 4 (FABP4) is a fatty chaperone, which induced during adipocyte differentiation. Previously we have shown that FABP4 in endothelial cells by the NOTCH1 signalling pathway, latter of involved mechanisms resistance to antiangiogenic tumour therapy. Here, investigated role metabolism and angiogenesis. We analysed effect transient knockdown human umbilical vein on metabolism, viability Through therapeutic delivery siRNA targeting mouse FABP4, growth blood vessel...
Abstract Background Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing potential repurposing this drug are underway. Transcriptomic profiling tumour samples is an excellent tool to understand bioactivity, identify candidate biomarkers assess for mechanisms resistance therapy. Methods Thirty-six untreated primary breast were recruited a window study transcriptomic carried out before...
Abstract Angiogenesis, the formation of new blood vessels by endothelial cells, is a finely tuned process relying on balance between promoting and repressing signalling pathways. Among these, Notch critical in ensuring appropriate response cells to pro-angiogenic stimuli. However, downstream targets pathways effected Delta-like 4 (DLL4)/Notch their subsequent contribution angiogenesis are not fully understood. We found that Rho GTPase, RHOQ, induced DLL4 silencing RHOQ results abnormal...
Genome-wide RNA expression profiling has yielded tumor subtypes with strong predictive or prognostic value for a wide variety of cancers. Recently, breast cancer two classifiers have been adopted by the World Health Organization (WHO) and approved Food Drug Administration (FDA). Also on basis DNA copy number profiles, different prognosis described, but not yet led to clinical implementation. The genomic revolution caused next generation sequencing samples presents additional mutation,...